Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Interest & Investment Income: 2023-2024

Historic Interest & Investment Income for Denali Therapeutics (DNLI) over the last 2 years, with Dec 2024 value amounting to $15.2 million.

  • Denali Therapeutics' Interest & Investment Income rose 15.48% to $15.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $64.6 million, marking a year-over-year increase of 25.49%. This contributed to the annual value of $64.6 million for FY2024, which is 25.49% up from last year.
  • Latest data reveals that Denali Therapeutics reported Interest & Investment Income of $15.2 million as of Q4 2024, which was down 5.21% from $16.0 million recorded in Q3 2024.
  • Over the past 5 years, Denali Therapeutics' Interest & Investment Income peaked at $17.6 million during Q2 2024, and registered a low of $11.0 million during Q1 2023.
  • Over the past 2 years, Denali Therapeutics' median Interest & Investment Income value was $14.8 million (recorded in 2023), while the average stood at $14.5 million.
  • Data for Denali Therapeutics' Interest & Investment Income shows a peak YoY soared of 44.22% (in 2024) over the last 5 years.
  • Denali Therapeutics' Interest & Investment Income (Quarterly) stood at $13.1 million in 2023, then increased by 15.48% to $15.2 million in 2024.
  • Its last three reported values are $15.2 million in Q4 2024, $16.0 million for Q3 2024, and $17.6 million during Q2 2024.